Search results
Showing 1111 to 1125 of 1336 results for primary care
Biodegradable subacromial spacer insertion for rotator cuff tears (IPG775)
Evidence-based recommendations on biodegradable subacromial spacer insertion for rotator cuff tears. This involves inserting a balloon-shaped device between the top of the shoulder blade and the upper arm bone to reduce pain and improve shoulder function.
View recommendations for IPG775Show all sections
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)
Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults. This involves placing a new bioprosthetic valve inside a failing bioprosthetic valve.
View recommendations for IPG653Show all sections
Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis (IPG726)
Evidence-based recommendations on supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis in adults. This involves replacing a hip using smaller cuts than are used in standard surgery.
View recommendations for IPG726Show all sections
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.
well-established systems for the assessment of mental states, in primary and secondary care services, for common mental...
Evidence-based recommendations on encorafenib (Braftovi) plus cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.
This guideline has been updated and replaced by NICE guideline CG113.
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
notes(if applicable) Why this is important:- As a gluten-free diet is the primary treatment option for people with coeliac disease, it...
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued [GID-TA10105]
for admission to an intensive care unit (ICU). The most commonly used medication is phenytoin. This should be used with...
Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)
Evidence-based recommendations on ibrutinib (Imbruvica) for treating relapsed or refractory mantle cell lymphoma in adults.
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)
Evidence-based recommendations on gemtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over.